Confirming an actual cancer diagnosis in patients flagged as potentially having a malignancy by a multicancer blood test typically required multiple imaging scans and laboratory tests, suggested ...
IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences (CAI)® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a ...
Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, ...
Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection ...
Most cancer deaths occur after the tumor has metastasized to distant sites. The process of metastasis takes decades to develop, providing a large window of opportunity for earlier detection before the ...
A session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit addressed the promise and potential drawbacks of multicancer early detection (MCED) testing for patients in the primary care ...
In 2020 (the most recent year for which federal U.S. incidence data are available), 1,603,844 new cases of cancer were reported and 602,347 people died of cancer. Despite substantial progress in ...
In Partnership with ATC Genomics, the Company Presented One of Asia's Largest Real-World Datasets (n=12,281) for AI-Powered Multi-Cancer Early Detection (MCED) and Showcased its Clinically Validated ...
In a recent study published in Cancer Cell, researchers assessed several approaches for a circulating cell-free deoxyribonucleic acid (cfDNA)-based multi-cancer early detection (MCED) test. Defining ...
An Asian multi-regional registry study of rare cancers: The MASTER KEY ASIA and MASTER KEY Japan projects. Pooled accuracy of prediction of tissue-of-origin (TOO) and frequently ‘misclassified as’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results